the aid library

Filter

848

Download

View PDF

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended

World Health Organization (2016) C_WHO

Download

View PDF

Democratic Republic of Timor-Leste Ministry of Health - Comprehensive TB Guidelines for National Tuberculosis Program, V Edition

Government of Timor-Leste; World Health Organization (2023) CC

The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death. The salient observations are as follows: In 2018, 487 (12.5%) of the ... more

Download

View PDF

For Proper Disposal Hospital Waste

Jorge Emmanuel and Ruth Stringer Health Care Without Harm (2007)

A Global Inventory of Alternative Medical Waste Treatment Technologies

Download

View PDF

Cleaning and disinfection of environmental surfaces in the context of COVID-19
recommended

World Health Organisation (2020) C_WHO

The purpose of this document is to provide guidance on the cleaning and disinfection of environmental surfaces in the context of COVID-19. This guidance is intended for health care professionals, public health professionals and health authorities that are developing and implementing policies and sta ... more

Download

View PDF

Tool to assess the association between injections and infections

World Health Organization (2001)

Download

View PDF

Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025

World Health Organization; UNICEF (2013) C_WHO

The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)

Download

View PDF

Logistics of Health Care Waste Management

USAID (2009) CC

Information and Approaches for developing Country Settings

Download

View PDF

Water, sanitation, hygiene and health. A primer for health professionals

World Health Organization WHO (2019) C_WHO

This primer aims to guide health professionals on engaging with WASH-related issues. It gives an overview of WASH interventions and the status of WASH services globally and outlines key linkages with health. It provides examples of key actions that health actors can take to ensure WASH efforts effec ... more

Download

View PDF

Water, sanitation and hygiene in health care facilities: practical steps to achieve universal access to quality care

World Health Organization WHO; UNICEF (2019) C_WHO

Download

View PDF

Клінічна Допомога при Важкій Гострій Респіраторній Iнфекції
recommended

World Health Organization WHO (2020) C_WHO

Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation

Download

View PDF

Guidelines for the clinical management of severe illness from influenza virus infections

World Health Organization WHO (2022) C_WHO

The purpose of this document is to guide clinicians in the care of patients with or at risk of severe illness from influenza virus infection, including those caused by seasonal influenza viruses, pandemic influenza viruses and zoonotic (novel influenza A) viruses.

Download

View PDF

Pneumonia: The forgotten killer for the children

Wardlaw, Tessa M.; Johansson, Emily White; Hodge, Matthew UNICEF; World Health Organization (2006)

Pneumonia kills more children than any other illness – more than AIDS, malaria and measles combined. Over 2 million children die from pneumonia each year, accounting for almost 1 in 5 under five deaths worldwide. Yet, little attention is paid to this disease. This joint UNICEF/WHO report examines ... more

Download

View PDF

Клиническое ведение тяжелой острой респираторной инфекции: методическое пособие. Версия, адаптированная для борьбы с COVID-19
recommended

World Health Organization WHO (2020) C_WHO

Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation

External Link

Global burden of childhood pneumonia and diarrhoea

Christa L Fischer Walker, Igor Rudan, Li Liu, Harish Nair, et al. The Lancet (2013) C1

Lancet 2013; 381: 1405–16 Series: Childhood Pneumonia and Diarrhoea no.1

Download

View PDF

SSI Prevention – SURGICAL SITE SKIN PREPARATION AND SURGICAL HAND PREPARATION

Surgical Unit-based Safety Program World Health Organisation (WHO) (2018) C_WHO

Download

View PDF

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ... 2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Download

View PDF

Solution Hydro-Alcoolique - Formulation 1 OMS

Pharma-Ed Pharma-Ed (2015) C2

30.03.2015

Download

View PDF

International health regulations (‎2005)‎: state party self-assessment annual reporting tool, 2nd ed

World Health Organization WHO (2022) C_WHO

Second edition. AVailable in English, French, Spanish, Russian, Chinese and Portuguese

External Link

Health care waste management assessment tool

World Health Organization (2001)

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings recommended

Cleaning and disinfection of environmental surfaces in the context of COVID-19 recommended

Клінічна Допомога при Важкій Гострій Респіраторній Iнфекції recommended

Клиническое ведение тяжелой острой респираторной инфекции: методическое пособие. Версия, адаптированная для борьбы с COVID-19 recommended

WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health-care settings
recommended

Cleaning and disinfection of environmental surfaces in the context of COVID-19
recommended

Клінічна Допомога при Важкій Гострій Респіраторній Iнфекції
recommended

Клиническое ведение тяжелой острой респираторной инфекции: методическое пособие. Версия, адаптированная для борьбы с COVID-19
recommended